Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Pancreatic Cancer Lawsuits Reinstated for Incretin-Based Diabetes Drugs

January 2, 2018 By Law Offices of Thomas J. Lamb, P.A.


Background

Among the several different types of therapies indicated for treating type 2 diabetes are increatin mimetics.  The medications approved by the FDA that fall into this class of drugs are:

  • Byetta (exenatide)
  • Bydureon (exenatide)
  • Januvia (sitagliptin)
  • Janumet (sitagliptin)
  • Victoza (liraglutide)

Previous scientific studies suggested that these incretin-based diabetes drugs may carry an increased risk of developing pancreatic cancer, but the FDA has not added any such warnings to the drug labels.

 

Previous Lawsuits

In 2015, Judge Anthony Battaglia in the Southern District of California effectively shut down all federal court lawsuits alleging that Byetta, Januvia, Victoza, and the other drugs in this class caused pancreatic cancer in the patients who used them.  Over 700 of these cases were filed, and consolidated into the Incretin Mimetics Products Liability Litigation MDL.

The plaintiffs in these federal court cases argued that drug manufacturers knew of the risks of developing pancreatic cancer, yet failed to warn doctors and patients.

However, the federal judge ruled that there was sufficient evidence to establish that any requests to add pancreatic cancer warnings to the drug labels would not have been approved by the FDA.  He based his decision on the fact that the FDA concluded that “a causal association between the drugs and pancreatic cancer is indeterminate,” which “falls below the science-based regulatory standards that govern what must be included in product labeling.”

 

A Second Chance?

On December 6, 2017, a federal appeals court issued an opinion that reverses the judge’s 2015 ruling.  This is significant because it reinstates all of the lawsuits that were previously tossed out.

This decision was made on the basis that the plaintiffs’ attorneys were not given access to requested documents, nor were they allowed to present “newly discovered evidence” concerning animal studies and clinical trials at the time of the original trial.

While this is certainly good news for the plaintiffs, the cases will be tried by the same judge that originally tossed them out.  While the attorneys for the plaintiffs will be allowed to collect and present additional information, they still run into the issue of whether that information would have caused the FDA to require a label change for Byetta, Bydureon, Januvia, Janumet, and Victoza.

We will continue to monitor the legal news pertaining to Byetta, Bydureon, Januvia, Janumet, and Victoza and the upcoming new trials, and report on significant developments.  In the meantime, we encourage you to visit our website and complete a free case evaluation if you or someone you know has been diagnosed with pancreatic cancer after using one of these incretin-based diabetes drugs.

 

Written by: Heather Helmendach, Legal Assistant 
Law Offices of Thomas J. Lamb, P.A.

 

Drug Injury Watch: Side Effects News & Reports

Drug Injury Law: Medical & Legal Information

Filed Under: Unsafe Drugs Tagged With: Bydureon, Byetta, drug injury lawsuits, increatin mimetics, incretin-based diabetes drugs, Janumet, Januvia, new trials incretin therapy diabetes drugs, Pancreatic Cancer, side effects, Victoza

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.